Category C . Reproduction studies performed in rats and rabbits at oral doses up to 8 times the maximum human dose did not reveal evidence of teratogenicity. In the rat, however, this multiple of the human dose resulted in decreased pregnancies and in the retarded development of fetuses. These effects are thought to be due to an inhibition or delay in implantation which is also observed in rodents administered other antipsychotic drugs. In the rabbit, maternal toxicity, mortality , decreased weight gain, and embryotoxicity including increased resorptions were dose-related. Because animal reproduction studies are not always predictive of human response, pimozide should be given to a pregnant woman only if the potential benefits of treatment clearly outweigh the potential risks.
PGxOne™ Plus Pharmacogenomics Test PGxOne™ Plus is a pharmacogenomics test that predicts how patients will respond to drug therapy based on their individual genetic makeup. Differences between individuals can affect drug absorption, metabolism, or activity. Therefore, while one treatment regimen may work well for one individual, the same regimen may cause adverse effects for other individuals. 1, 2 PGxOne™ Plus comprehensively screens 50 well-established pharmacogenomic genes in a single, cost-effective test that provides medically actionable and clinically relevant data, thus allowing physicians to make effective treatment decisions. Expanding beyond pharmacogenomics, PGxOne™ Plus reports potential adverse interactions of the patient’s current medications.